Zaman Ashraf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zaman Ashraf has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Banzeer Ahsan Abbasi
Rawalpindi Women University
2 shared publications- Farhat Yasmeen
Department of Biosciences, University of Wah, Wah Cantt, Pakistan
2 shared publications - Iftikhar Ali
University of Swat
2 shared publications Javed Iqbal
Bacha Khan University
2 shared publications- Mamoona Munir
Rawalpindi Women University
2 shared publications - Muhammad Atif
Department of Chemistry, Allama Iqbal Open University, Islamabad, Pakistan
2 shared publications
Latest Publications
- 3 November 2026
- Published by Springer Nature in Journal of the Iranian Chemical Society
- Vol. 23 (11) , 376
CeO₂@GO/rGO nanocomposites for accelerated photocatalytic degradation of yellow 27 dye: unveiling the role of a sustainable catalyst
- 3 November 2026
- Published by Springer Nature in Journal of the Iranian Chemical Society
- Vol. 23 (11) , 376
CeO₂@GO/rGO nanocomposites for accelerated photocatalytic degradation of yellow 27 dye: unveiling the role of a sustainable catalyst
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-32
Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib
Poly(ADP-ribose) polymerase (PARP) inhibition has emerged as a prominent approach in cancer treatment, leading to the development of several poly(ADP-ribose) polymerase inhibitors (PARPi), which have demonstrated substantial progress in clinical trials and efficacy in the management of ovarian cancer (OC), breast cancer (BC), and solid tumors (STs). These PARPi are approved for several cancers, including BC and OC. Among PARPi, Talazoparib (Talzenna®) is a potent therapy for patients with locally advanced or metastatic BC (mBC) with germline BRCA mutations (gBRCAm) and HER2-negative status, demonstrating the highest potency (IC50 = 0.57 nM), which is 4–10 times lower than that of other PARP inhibitors; olaparib (2.0 nM), rucaparib (1.9 nM), and veliparib (4.7 nM), indicating superior efficacy. This review describes the role of BRCA1/2 in BC and OC, highlighting key discovery milestones and providing an overview of available PARP inhibitors (PARPi) at various stages of development. Additionally, it details the discovery and development of talazoparib, one of the key PARPis, its current clinical status, and therapeutic implications. The latest advancements in talazoparib research, including all related clinical trials (Phase 1–3) for the treatment of BC, OC, and other solid tumors (STs), are also summarized. A comprehensive analysis of all clinical trials involving talazoparib, whether as monotherapy or in combination with other drugs, elucidates its potential to improve clinical outcomes, address drug resistance, and explore synergistic combinations with other PARPi or novel agents, thereby providing insights into the clinical utility of talazoparib.
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-32
Open AccessAdvances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib
Poly(ADP-ribose) polymerase (PARP) inhibition has emerged as a prominent approach in cancer treatment, leading to the development of several poly(ADP-ribose) polymerase inhibitors (PARPi), which have demonstrated substantial progress in clinical trials and efficacy in the management of ovarian cancer (OC), breast cancer (BC), and solid tumors (STs). These PARPi are approved for several cancers, including BC and OC. Among PARPi, Talazoparib (Talzenna®) is a potent therapy for patients with locally advanced or metastatic BC (mBC) with germline BRCA mutations (gBRCAm) and HER2-negative status, demonstrating the highest potency (IC50 = 0.57 nM), which is 4–10 times lower than that of other PARP inhibitors; olaparib (2.0 nM), rucaparib (1.9 nM), and veliparib (4.7 nM), indicating superior efficacy. This review describes the role of BRCA1/2 in BC and OC, highlighting key discovery milestones and providing an overview of available PARP inhibitors (PARPi) at various stages of development. Additionally, it details the discovery and development of talazoparib, one of the key PARPis, its current clinical status, and therapeutic implications. The latest advancements in talazoparib research, including all related clinical trials (Phase 1–3) for the treatment of BC, OC, and other solid tumors (STs), are also summarized. A comprehensive analysis of all clinical trials involving talazoparib, whether as monotherapy or in combination with other drugs, elucidates its potential to improve clinical outcomes, address drug resistance, and explore synergistic combinations with other PARPi or novel agents, thereby providing insights into the clinical utility of talazoparib.
- 12 January 2026
- Published by Springer Nature in Iranian Journal of Science
- Vol. 50 (3) , 1001-1015
N-Doped Fluorescent Organic Probes: Facile Synthesis and Multifunctional Applications in TNX Sensing, Wastewater Treatment, and Luminescent Films
- 12 January 2026
- Published by Springer Nature in Iranian Journal of Science
- Vol. 50 (3) , 1001-1015
N-Doped Fluorescent Organic Probes: Facile Synthesis and Multifunctional Applications in TNX Sensing, Wastewater Treatment, and Luminescent Films
- Open Access
- 5 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Modulating absorption and emission of smart fluorescent organic probes through tailored physicochemical properties
The newly fabricated fluorescent organic nanoparticles (FONs) with size 80.94 nm as renowned contender has facile synthesis, robust tunable fluorescence, unique optical properties and great potential in sensing at trace level. The optical properties of fluorescent organic probe depend on the experimental parameters e.g. synthesis routes, doping, solvatochromism, temperature, pH and the types of precursors, which influence the surface state and graphitic carbon-cluster. The incorporation of N-atom modified the intrinsic properties (π–π∗, n–π∗ electronic transition) and caused the change in energy level Δ\(\:{E}_{g}\) from 2.81 eV to 2.43 eV. The fluorescent intensity decreased as increasing or decreasing from pH ~ 7 due to change in extended delocalization. The temperature-dependent florescence response showed differently in different solvents owing to various interactions between surface state of fluorescent organic probe and solvents. The fluorescent organic probe demonstrated excellent qualitative and visual detection of water content in organic solvents due to solvatochromism. This strategy enables the bathochromic shift Δλem in fluorescent organic probe for the generation of multicolor. Moreover, the fluorescent organic probe can be used as a fluorescent ink for anti-counterfeiting. This research aims to provide a detailed examination of experimental parameters as a valuable tool for the synthesis of fluorescent organic nanoparticles FONs.- 5 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessModulating absorption and emission of smart fluorescent organic probes through tailored physicochemical properties
The newly fabricated fluorescent organic nanoparticles (FONs) with size 80.94 nm as renowned contender has facile synthesis, robust tunable fluorescence, unique optical properties and great potential in sensing at trace level. The optical properties of fluorescent organic probe depend on the experimental parameters e.g. synthesis routes, doping, solvatochromism, temperature, pH and the types of precursors, which influence the surface state and graphitic carbon-cluster. The incorporation of N-atom modified the intrinsic properties (π–π∗, n–π∗ electronic transition) and caused the change in energy level Δ\(\:{E}_{g}\) from 2.81 eV to 2.43 eV. The fluorescent intensity decreased as increasing or decreasing from pH ~ 7 due to change in extended delocalization. The temperature-dependent florescence response showed differently in different solvents owing to various interactions between surface state of fluorescent organic probe and solvents. The fluorescent organic probe demonstrated excellent qualitative and visual detection of water content in organic solvents due to solvatochromism. This strategy enables the bathochromic shift Δλem in fluorescent organic probe for the generation of multicolor. Moreover, the fluorescent organic probe can be used as a fluorescent ink for anti-counterfeiting. This research aims to provide a detailed examination of experimental parameters as a valuable tool for the synthesis of fluorescent organic nanoparticles FONs. - 26 March 2025
- Published by Springer Nature
- p. 339-381
Omics Approaches for Efficient Bioenergy Forage Crop
- 26 March 2025
- Published by Springer Nature
- p. 339-381
Omics Approaches for Efficient Bioenergy Forage Crop
- Open Access
- 12 July 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (31) , 22769-22780
Elucidating bis-pyrimidines as new and efficient mushroom tyrosinase inhibitors: synthesis, SAR, kinetics and computational studies
In this study, a series of novel bis-pyrimidine derivatives (1P–8P) were designed, synthesized, characterized, and investigated for their in vitro inhibitory activity against mushroom tyrosinase.
- 12 July 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (31) , 22769-22780
Open AccessElucidating bis-pyrimidines as new and efficient mushroom tyrosinase inhibitors: synthesis, SAR, kinetics and computational studies
In this study, a series of novel bis-pyrimidine derivatives (1P–8P) were designed, synthesized, characterized, and investigated for their in vitro inhibitory activity against mushroom tyrosinase.
- Open Access
- 1 January 2024
- Published by IMAPS - International Microelectronics Assembly and Packaging Society in International Symposium on Microelectronics
- Vol. 2024 (Symposium) , 434-443
Synthesis of Highly Stable Near-Infrared FAPbI3 Perovskite doped with 5-AVA and its Applications in NIR Light-Emitting Diodes for Bioimaging
The continuously increasing external quantum efficiencies of Perovskite light-emitting diodes (LEDs) have received significant interest in the scientific community. The need for monitoring and medical diagnostics has experienced a steady growth in recent years, primarily caused by older people and an increasing number of heart attacks, tumors, and cancer disorders among patients. The application of Perovskite near-infrared light-emitting diode (PeNIRLEDs) has exhibited considerable efficacy in bioimaging, particularly in the visualization and examination of blood arteries, blood clots, and tumors. PeNIRLEDs exhibit exciting potential in the field of blood vessel imaging because of their advantageous attributes, including improved depth penetration and less scattering in comparison to visible light. In this study we synthesized of FAPbI3 Perovskite doped with different concentrations of 5-Aminovaleric acid (5-AVA) 1-6 mg. The incorporation of 5-AVA as a dopant during the FAPbI3 Perovskite formation, it influences the FAPbI3 Perovskite’s structural and optical properties. While improve the FAPbI3 Perovskite’s stability, photoluminescence efficiency, and charge transport characteristics. We found resulting PL emission peak wavelength of 850 nm and bandwidth of 44 nm along with a calculated quantum yield of 75%.The incorporation of 5-AVA-modified FAPbI3 Perovskite into LEDs will show promising results, enhancing device efficiency, color purity, and stability. Making it suitable for various medical applications, including subcutaneous deep vein imaging, blood flow visualization, and tumor illumination.
- 1 January 2024
- Published by IMAPS - International Microelectronics Assembly and Packaging Society in International Symposium on Microelectronics
- Vol. 2024 (Symposium) , 434-443
Open AccessSynthesis of Highly Stable Near-Infrared FAPbI3 Perovskite doped with 5-AVA and its Applications in NIR Light-Emitting Diodes for Bioimaging
The continuously increasing external quantum efficiencies of Perovskite light-emitting diodes (LEDs) have received significant interest in the scientific community. The need for monitoring and medical diagnostics has experienced a steady growth in recent years, primarily caused by older people and an increasing number of heart attacks, tumors, and cancer disorders among patients. The application of Perovskite near-infrared light-emitting diode (PeNIRLEDs) has exhibited considerable efficacy in bioimaging, particularly in the visualization and examination of blood arteries, blood clots, and tumors. PeNIRLEDs exhibit exciting potential in the field of blood vessel imaging because of their advantageous attributes, including improved depth penetration and less scattering in comparison to visible light. In this study we synthesized of FAPbI3 Perovskite doped with different concentrations of 5-Aminovaleric acid (5-AVA) 1-6 mg. The incorporation of 5-AVA as a dopant during the FAPbI3 Perovskite formation, it influences the FAPbI3 Perovskite’s structural and optical properties. While improve the FAPbI3 Perovskite’s stability, photoluminescence efficiency, and charge transport characteristics. We found resulting PL emission peak wavelength of 850 nm and bandwidth of 44 nm along with a calculated quantum yield of 75%.The incorporation of 5-AVA-modified FAPbI3 Perovskite into LEDs will show promising results, enhancing device efficiency, color purity, and stability. Making it suitable for various medical applications, including subcutaneous deep vein imaging, blood flow visualization, and tumor illumination.